We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

By LabMedica International staff writers
Posted on 28 Mar 2024
Print article
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane inside the ovary. Often discovered by chance in women without symptoms, ovarian cysts can also be detected during evaluations for pelvic pain. Surgical removal is a common treatment, with 5%-10% of women with ovarian cysts undergoing surgery. Of these, 13%-21% are found to have cancer upon intra-operative evaluation. The Frozen Section procedure for intra-operative evaluation that involves the slicing and microscopic examination of freeze-dried ovarian tissue aids in this determination but suffers from limitations such as unavailability, a lengthy process of up to 60 minutes, and low accuracy. The need for a swift method to differentiate between benign and malignant cysts during surgery is critical to inform management and treatment choices effectively.

INEX Innovate (Singapore) has now introduced the OvaCis Rapid Test, a novel intraoperative in vitro diagnostic (IVD) device. This test, with the ability to rapidly distinguish benign from malignant ovarian cysts within just 15 minutes, provides surgeons with immediate diagnostic data. This enables them to make quicker, more informed decisions and reduce unnecessary surgical procedures. The OvaCis Rapid Test has received regulatory approval from the Health Sciences Authority (HSA) in Singapore and is also CE-marked, and MHRA, UK registered.

Related Links:
INEX Innovate

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fixed Speed Tube Rocker
GTR-FS
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.